The Making of Max Planck

The Making of Max Planck By Elie DolginIn 1945, the Kaiser Wilhelm Society, Germany's premier science research institution, was in tatters. It was even at risk of being axed after the Second World War, but leading German scientists convinced the allies to rebuild and rebrand the renowned research organization. So an 86- year-old Max Planck once again assumed the presidency, after the Nazi regime forced him from the post in 1937. As part of the society's makeover, Planck, the

Written byElie Dolgin
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

By Elie Dolgin

In 1945, the Kaiser Wilhelm Society, Germany's premier science research institution, was in tatters. It was even at risk of being axed after the Second World War, but leading German scientists convinced the allies to rebuild and rebrand the renowned research organization. So an 86- year-old Max Planck once again assumed the presidency, after the Nazi regime forced him from the post in 1937. As part of the society's makeover, Planck, the founder of quantum theory, offered his own name. In 1946, he served as the first honorary president of the Max Planck Society (MPS) during its early development in postwar Germany's British zone.

Planck, however, passed away less than a year before the society's first official meeting in February 1948 in Göttingen. At that time, his eponymous society comprised only 25 small institutes with a combined budget of around $5-6 million (about $50 million in today's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies